Sugar-sweetened drinks linked to 1 in 10 new diabetes cases

The consumption of sugar-sweetened beverages is driving millions of diabetes and heart disease cases worldwide, with significant regional health inequalities.

A new report questions whether digital diabetes programs are worth the cost

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Employers, insurers and investors have long been

March 27, 2024

Why isn’t Vertex declaring success for its non-opioid pain drug in a late-stage trial?

Normally when a company scores on a primary endpoint in a Phase III trial, those results are released as soon as possible to not only

October 24, 2023

Argenx reports Vyvgart sales streak, bolstered by launch in rare neuro disorder

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.